26.07.19
We are pleased to inform you of a study opportunity available to NPC patients and their families:
Clinical Outcomes Solutions (COS), is a research company conducting research into Niemann-Pick type C (NPC) on behalf of a sponsor, Orphazyme A/S, a pharmaceutical company studying NPC...
22.07.19
Following the encouraging regulatory agency feedback, Orphazyme plans to introduce an Early Access
Program for NPC in the fall of 2019, to further accelerate access to treatment with arimoclomol for people
living with NPC...
18.07.19
Anders Hinsby: "I am writing to personally share the news that I will be resigning my position as Orphazyme’s Chief Executive Officer effective October 1, 2019..."
Read more15.07.19
This year the NPUK Interactive Workshop will take place on the 20th September at Wyboston Lakes, Bedfordshire - and will as ever be a fantastic opportunity for clinicians, health professionals and scientists working in the Niemann-Pick field to meet together under one roof...
Read more05.07.19
Our Annual Family Conference and Interactive Workshop on Niemann-Pick Diseases is the largest event in the NPUK calendar, bringing together affected individuals, families, health and research professionals under one roof...
Read more
